Abbott’s fourth-quarter 2018 revenue fell short of Wall Street expectations due to lower sales of generic drugs in emerging markets as well as a strong dollar, and the healthcare company forecast first-quarter 2019 earnings below analysts’ estimates.
Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.
Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.
Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.
Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.
Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.
Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.
Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.
Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.